Our study demonstrated that metoclopramide (as dopaminergic antagonist) has a very high capacity to induce hyperprolactinemia in rat, indeed the tumour growth accelerated during the observation period and this effect could be influenced or stimulated by PRL release. The gene discussed is PRL; the disease is neoplasm.